Novartis has reported positive results from a Phase lllb trial evaluating Cosentyx (secukinumab) in comparison with Stelara (ustekinumab) for the treatment of psoriasis.

Findings of the CLARITY trial showed the superiority of Cosentyx (secukinumab) compared with Stelara (ustekinumab) in delivering clear and almost clear skin in adults with moderate-to-severe plaque psoriasis at 12 weeks.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Results also showed that Cosentyx was found to be more effective than Stelara in achieving sustained skin clearance (psoriasis area and severity index90) at week 52 of the trial.

In addition, Cosentyx demonstrated significantly improved results than Stelara in delivering clear and almost clear skin at 12 weeks and 16 weeks.

“Cosentyx demonstrated significantly improved results than Stelara in delivering clear and almost clear skin at 12 weeks and 16 weeks.”

Novartis further noted that 66.5% and 72.3% of patients treated with Cosentyx achieved both co-primary endpoints PASI 90 and Investigator’s Global Assessment (IGA) mod 2011 0/1 respectively. This compared to 47.9% and 55.4% patients respectively treated with Stelara.

The CLARITY trial is a 52-week, multicentre, randomised, double-blind study to demonstrate the effectiveness of Cosentyx (secukinumab) 300mg vs Stelara (ustekinumab) in moderate-to-severe plaque psoriasis patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its co-primary endpoints were 90% or more improvement from Baseline PASI 90 and mod 2011 0/1 (clear or almost clear) response rates at week 12.

Key secondary endpoints included demonstrating the effectiveness of secukinumab vs ustekinumab with respect to PASI 75 at week four, PASI 75 and 100 at week 12; and PASI 75, 90, 100 and IGA mod 2011 0/1 at week 16.

The trial has met all these endpoints, noted Novartis.